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BAG-1 is a multifunctional protein that interacts with a wide range of target molecules to regulate apoptosis, proliferation,
transcription, metastasis and motility. Interaction with chaperone molecules may mediate many of the effects of BAG-1. The
pathways regulated by BAG-1 play key roles in the development and progression of cancer and determining response to
therapy, and there has been considerable interest in determining the clinical signiﬁcance of BAG-1 expression in malignant
cells. There is an emerging picture that BAG-1 expression is frequently altered in a range of human cancers relative to normal
cells and a recent report suggests the exciting possibility that BAG-1 expression may have clinical utility as a prognostic marker
in early breast cancer. However, other studies of BAG-1 expression in breast cancer and other cancer types have yielded
differing results. It is important to view these ﬁndings in the context of current knowledge of BAG-1 expression and function.
This review summarises recent progress in understanding the clinical signiﬁcance of BAG-1 expression in cancer in light of our
understanding of BAG-1 function.
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BAG-1 STRUCTURE
BAG-1 proteins are expressed as multiple isoforms generated by
alternate translation initiation from a single mRNA (Packham et
al, 1997; Takayama et al, 1998; Yang et al, 1998). The major
human BAG-1 isoform, BAG-1S, initiates at an internal AUG
codon, whereas translation of the larger BAG-1L and BAG-1M
proteins initiate at upstream CUG and AUG codons, respectively.
The proteins therefore share a common C-terminus and the larger
isoforms have additional N-terminal sequences (Figure 1).
Various domains have been identiﬁed within BAG-1 proteins.
We initially identiﬁed a potential nuclear localisation signal
(NLS) within the unique N-terminal domain of BAG-1L, consistent
with the predominantly nuclear localisation of this isoform (Pack-
ham et al, 1997; Takayama et al, 1998; Yang et al, 1998; Brimmell
et al, 1999). By contrast, BAG-1S and BAG-1M lack this sequence
and BAG-1S is largely located in the cytoplasm whilst BAG-1M
partitions between the nucleus and cytoplasm (Packham et al,
1997; Takayama et al, 1998; Yang et al, 1998). The nuclear/cyto-
plasmic distribution of BAG-1 isoforms is regulated under some
conditions and it is important to recognise that nuclear BAG-1
immunostaining in cancer cells may not be a reliable measure of
BAG-1L expression. For example, BAG-1M relocates from the cyto-
plasm to the nucleus after heat shock and in response to hormonal
stimulation (Schneikert et al, 1999; Zeiner et al, 1999). Thus,
nuclear BAG-1 expression may indicate either high levels of
BAG-1L or relocalisation of BAG-1S or BAG-1M to the nucleus
in response to speciﬁc signals in the tumour microenvironment.
All BAG-1 isoforms contain a C-terminal ‘BAG domain’ which
plays a key role in mediating many BAG-1 functions (Figure 1). This
domain of approximately 100 amino-acid residues deﬁnes a family of
related BAG proteins conserved throughout phylogeny, of which
there are at least six in the human (Takayama and Reed, 2001;
Sondermann et al, 2001). The core of the BAG domain comprises
two anti-parallel alpha-helices that mediate interaction with the
HSC70 and HSP70 heat shock proteins (Briknarova et al, 2001;
Sondermann et al, 2001), molecular chaperones that bind proteins
in non-native states assisting them to reach functional conﬁrmations.
HSC70 and HSP70 proteins comprise a peptide-binding domain that
interacts with denatured polypeptides and a regulatory ATPase
domain. BAG-1 interacts with the ATPase domain, leaving the
peptide-binding domain available for further interactions with
protein substrates. BAG-1 regulates the chaperone function of
HSC70 and HSP70 (Hohfeld, 1998) and mutation of speciﬁc
amino-acid residues important for binding to chaperone proteins
abrogates at least some BAG-1 functions (Briknarova et al, 2001).
The BAG-1 C-terminus also mediates interaction with the
serine/threonine kinase Raf-1, which is normally activated by
RAS to stimulate the mitogen-activated protein (MAP) kinase
signalling cascade. This signalling pathway is important for prolif-
eration and survival, and BAG-1 activates Raf-1 independent of
RAS (Song et al, 2001). Thus, BAG-1 overexpression provides a
potential mechanism by which tumours lacking oncogenic RAS
mutations might activate MAP kinase pathway mediated prolifera-
tive and survival signals. Raf-1 and HSP70 interact at partially
overlapping sites and therefore their binding to BAG-1 is competi-
tive.
In addition to these direct binding partners, several other
proteins have been reported to interact with BAG-1 (Figure 2),
including nuclear hormone receptors (NHR), the anti-apoptotic
Bcl-2 protein and some tyrosine kinase receptors such as the hepa-
tocyte growth factor and platelet derived growth factor receptors
(for reviews see Cato and Mink, 2001; Takayama and Reed,
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binding activities of HSC70/HSP70 (Hohfeld, 1998).
All BAG-1 isoforms contain a ubiquitin-like domain (ULD),
similar to ubiquitin and ubiquitin-like proteins that appears to
be essential for at least some biological effects (Luders et al,
2000; Hohfeld et al, 2001; Takayama and Reed, 2001). Ubiquitin
is a small protein that when covalently attached to target proteins
via the action of ubiquitin E3 ligases serves to target proteins for
ATP-dependent degradation via the proteasome, the major non-
lysosomal proteolytic complex. Although the precise function of
the ULD in BAG-1 is unknown, BAG-1 isoforms are very stable
proteins suggesting that they are not generally targets for degrada-
tion by the ubiquitin/proteasome system (Luders et al, 2000) and
are not covalently attached to other proteins. Other ULD-contain-
ing proteins are important for regulating ubiquitylation/proteolysis
and consistent with this, BAG-1 interacts with the E3 ligases CHIP
and Siah-1 and stimulates CHIP-mediated ubiquitylation of
substrates such as Raf-1 (Demand et al, 2001). BAG-1 interacts
with the proteasome. The amino-terminus of BAG-1 is required
for this interaction, and one potential mechanism of action of
BAG-1 is by linking chaperone molecules with the proteasome
(Luders et al, 2000; Hohfeld et al, 2001).
BAG-1 proteins contain different numbers of copies of repeats
rich in acidic amino-acids. Human BAG-1L and BAG-1M contain
10 copies whereas BAG-1S contains four (Packham et al, 1997).
The function of the repeats remains unclear since this part of
the molecule is not essential for suppression of apoptosis, but is
required for regulating glucocorticoid receptor (GR)-dependent
transcription (Schneikert et al, 1999).
BAG-1 FUNCTION
Overexpression of BAG-1 suppresses activation of caspases and
apoptosis induced by a very broad range of agents in different cell
types (Hohfeld, 1998; Takayama and Reed, 2001), for example
chemotherapeutic agents, radiation and growth factor withdrawal.
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Figure 1 Schematic diagram of the human BAG-1 isoforms. The BAG-1 mRNA and the position of the alternate translation initiation sites that give rise to
the three human BAG-1 isoforms is shown at the top. The domain structure of the BAG-1 isoforms is shown underneath (NLS, nuclear localization se-
quence; ULD, ubiquitin-like domain).
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Figure 2 BAG-1 binding partners and functions. BAG-1 interaction partners are indicated. Some of these interactions are direct, whereas others are
probably mediated via binding to chaperone molecules, e.g., NHR. Interactions of BAG-1 with chaperones, E3 ligases and the proteasome suggest a key
role in regulating the ubiquitin/proteasomal degradation system. Biological activities ascribed to BAG-1 are indicated below along with some potential
molecular targets that might contribute to these effects. However, it is important to note that deﬁnitive evidence linking speciﬁc BAG-1 target molecules
to biological responses is often lacking.
BAG-1 and human cancer
RI Cutress et al
835
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(8), 834–839Therefore, in addition to contributing to reduced cell death in
cancer development, BAG-1 may also contribute to resistance to
important therapeutic modalities. The ﬁnding that BAG-1 can
independently associate with Raf-1 or Bcl-2 provides at least two
potential mechanisms by which BAG-1 promotes survival (Song
et al, 2001). Heat shock proteins are also required for cell survival
and direct activation of these functions may also be important.
Suppression of apoptosis might contribute to the ability of BAG-
1 to promote metastatic spread (Takaoka et al, 1997; Yawata et
al, 1998). Alternatively, increased metastasis may be mediated by
enhanced cell motility (Yawata et al, 1998).
A second key function of BAG-1 of likely importance for cancer
is regulation of NHR. BAG-1 potentiates activity of oestrogen
receptors (ER) (R Cutress, PA Townsend and G Packham, unpub-
lished data), which mediates proliferative, and survival responses to
oestrogens in hormone dependent breast cancers and is the target
for anti-hormone therapies such as tamoxifen. The androgen
receptor (AR) is important in prostate cancer and BAG-1 increases
sensitivity of AR expressing cells to androgens and decreases sensi-
tivity to cyproterone acetate, an anti-androgen used clinically in the
treatment of prostate cancer (Froesch et al, 1998). BAG-1 also
modulates the activity of the vitamin D3 receptor (VDR) and
represses the activity of the retinoic acid receptor (RAR), thyroid
receptor (TR) and glucocorticoid receptor (GR) (Cato and Mink,
2001; Takayama and Reed, 2001). The effects of BAG-1 on some
nuclear hormone receptors requires the BAG-1 carboxy-terminus
and is likely to involve chaperone molecules which are known to
be important for NHR function. This has been demonstrated most
clearly for the AR where point mutations which ablate HSC70
binding prevent BAG-1 regulation (Briknarova et al, 2001). Effects
on NHR may be partly through BAG-1 triggered conformational
changes mediated by the heat shock proteins which may be impor-
tant for altering hormone binding capacity or afﬁnity. This is not
the case for all NHR however, as for example the HSC70 binding
region within the carboxy-terminus of BAG-1 is not required for
binding to the RAR (Cato and Mink, 2001). Biochemical and
mutagenic analyses therefore suggest that there may not be a single
mechanism to account for BAG-1’s modulation of nuclear
hormone receptor activity (Cato and Mink, 2001).
Although all BAG-1 isoforms interact with chaperone molecules
and possess anti-apoptotic activity, regulation of NHR is frequently
speciﬁc for the BAG-1L and/or BAG-1M proteins. For example,
only BAG-1L regulates the AR (Froesch et al, 1998) and ER (R
Cutress, PA Townsend and G Packham, unpublished data) whereas
both BAG-1L and BAG-1M regulate the GR. It is not clear whether
the frequent speciﬁcity for the larger BAG-1 isoforms stems from
the nuclear localisation of these proteins or from a requirement
for additional HSC/HSP70 independent functions encoded by the
amino-termini of these isoforms. For example, the acidic-rich
repeat has been suggested to be important for conferring GR-regu-
lating activity on BAG-1L and M (Schneikert et al, 1999).
Alternately, non-speciﬁc DNA binding mediated by the basic
amino-acid residues of the N-terminal NLS and/or transactivating
activity of the larger BAG-1 proteins might play a role in stabilising
receptor:DNA complexes and/or recruiting cooperating transcrip-
tion factors (Zeiner et al, 1999).
We are some way from a complete understanding of how BAG-1
exerts its effects on such a diverse array of biological pathways,
including proliferation, apoptosis and metastasis in addition to
its effects on transcription. As with NHR, many BAG-1 functions
are thought to be dependent on interaction with the HSC70 and/
or HSP70 chaperone molecules (Hohfeld, 1998). Despite this,
simple regulation of the refolding action of these proteins by
BAG-1 is not sufﬁcient for all the observed actions of BAG-1, since
other BAG-1 protein regions are required for biological effects in
addition to the BAG domain that binds HSC70/HSP70. BAG-1
may act as a scaffold molecule, to functionally link chaperone func-
tion with speciﬁc target molecules (Hohfeld et al, 2001; Takayama
and Reed, 2001). For example, BAG-1 may protect cells from the
apoptotic effects of cell stress induced by radiation or heat shock
by enhancing the delivery of chaperone-bound denatured proteins
to the proteasomal degradation system.
BAG-1 is the prototypical member of a family of BAG domain
containing proteins, which bind to and regulate chaperone mole-
cules. Although BAG-6 also contains a ULD, other BAG family
proteins contain distinct protein:protein interaction motifs, for
example BAG-3 contains a WW domain and PXXP motifs in addi-
tion to its BAG domain. Similar to the proposed role of BAG-1 in
linking chaperones and the proteasome, recruitment of chaperone
molecules to other molecular targets via speciﬁc BAG proteins
may represent a common theme of cell growth control, conserved
through evolution (Takayama and Reed, 2001).
Mechanisms of action of BAG-1 that do not occur through
direct HSC70/HSP70 binding, for example, the activation of Raf-
1 by BAG-1 are also likely to be important (Song et al, 2001).
The binding of HSP70 and Raf-1 for BAG-1 is competitive and
the high levels of HSP70 that accumulate in stressed cells may
displace Raf-1, shutting down important signals for survival and
proliferation. Therefore, BAG-1 isoforms may act as a ‘molecular
switch’ in signalling pathways, that direct cells towards different
states ‘depending on whether environmental conditions are hospi-
table or stressful’ (Song et al, 2001; Takayama and Reed, 2001).
BAG-1 AND BREAST CANCER
Given the impact of BAG-1 overexpression on multiple growth
control pathways, there has been considerable interest in studying
the signiﬁcance of BAG-1 in human cancer. Four large immunohis-
tochemical studies of the expression and clinical signiﬁcance of
BAG-1 in breast cancer have been reported and these are
summarised in Table 1 (Tang et al, 1999; Turner et al, 2001; Sjos-
trom et al, 2002; Townsend et al, 2002). Some of the results from
these studies are inconsistent and further studies are required to
fully understand the role of BAG-1 expression in breast cancer
(Cutress et al, 2001). A consistent ﬁnding is that relatively high
levels of cytoplasmic BAG-1 expression are detected in two thirds
or more cases of breast cancer. Changes in BAG-1 expression can
be detected in benign lesions such as sclerosing adenosis, and in
ductal carcinoma in situ suggesting that they might represent a
relatively early event in breast cancer development (Brimmell et
al, 1999). By contrast, the extent of nuclear BAG-1 expression
differs widely in these studies, possibly for reasons discussed below,
ranging from as low as 20% to almost 70%. Moreover, the propor-
tion of tumours with both nuclear and cytoplasmic expression
varies widely from just 1% to more than 60%.
A strong relationship between nuclear BAG-1 expression and
tumour grade/differentiation has been identiﬁed in two studies,
with relatively high levels of nuclear BAG-1 expression in low grade
tumours (Tang et al, 1999; Townsend et al, 2002). By contrast,
Turner et al (2001) reported no correlation between tumour grade
and BAG-1 expression. Correlations with other clinical markers,
such as oestrogen receptor alpha (ERa) and BCL-2 expression have
been reported in various studies, but these appear to be not as
strong as the correlation with grade and are more variably detected
(Table 1).
Turner et al (2001) reported an overall 10-year survival for
women with early stage breast cancer of 82% with high cytoplasmic
BAG-1 levels vs 42% survival with low BAG-1 levels. Cytoplasmic
BAG-1 status predicted outcome in both univariate and multivari-
ate analyses, and also retained predictive value in a subset of their
patients with pathologically negative lymph nodes. This is particu-
larly interesting since it was suggested that this might provide a
means by which node negative patients with a relatively poorer
prognosis could be selected for further adjuvant therapies, and
BAG-1 and human cancer
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such therapies with their concomitant side effects. This exciting
ﬁnding awaits conﬁrmation (Tang et al, 1999; Townsend et al,
2002). Tang et al (1999) found no correlations between BAG-1
expression and outcome in univariate analysis and conversely
reported that increased BAG-1 expression correlated with decreased
disease free and overall survival in a multivariate analysis
controlled for tumour differentiation. In our own study no correla-
tions were found between cytoplasmic BAG-1 and outcome
(Townsend et al, 2002). We did, however, observe a tendency for
patients with nuclear BAG-1 expression to have slightly (but not
statistically signiﬁcantly) improved outcomes, consistent with the
correlation we found with low tumour grade.
The ability of BAG-1 expression to predict response to adjuvant
therapy has currently only been assessed in one study. Sjostrom et
al (2002) found that BAG-1 expression did not predict time to
progression or overall survival in patients with advanced breast
cancer entered into a randomised controlled trial comparing doce-
taxel with sequential methotrexate and 5-ﬂuorouracil. BAG-1 status
therefore appears not to predict response to chemotherapy, but,
unlike other studies demonstrating prognostic signiﬁcance, BAG-
1 subcellular localisation was not analysed. Further work is
required to assess the ability of BAG-1 to predict response to adju-
vant therapy, in particular given the role of BAG-1 in modulation
of NHR function, and the importance of adjuvant hormonal ther-
apy in breast cancer.
BAG-1 AND OTHER MALIGNANCIES
BAG-1 expression has also been studied in a range of other cancer
types (Table 2). Rorke et al (2001) have studied the expression of
BAG-1 by immunohistochemistry in non-small cell lung cancer.
Consistent with studies in other tumour types they found that
approximately two thirds of tumours expressed high levels of
BAG-1. In particular they found no correlations between BAG-1
and clinico-pathological parameters, but did ﬁnd that, similar to
the study of Turner et al (2001) in breast cancer, cytoplasmic
expression of BAG-1 independently correlated with improved over-
all survival.
Several groups have studied expression of BAG-1 in human
squamous cell carcinomas. Yamauchi et al (2001) found that, in
contrast to breast and lung cancer, nuclear expression of BAG-1
in laryngeal tumours conferred a worse disease-free survival after
radiotherapy. In oral squamous cell carcinomas, Shindoh et al
(2000) demonstrated increased BAG-1 expression in tumour tissue
relative to adjacent normal epithelium in 60–80% of samples. By
contrast, our study of 64 oral squamous cell carcinomas and 17
samples of normal oral epithelium, revealed reduced nuclear
BAG-1 expression in oral squamous cell carcinomas (P=0.036)
compared to normal oral epithelium (Hague et al, 2002).
BAG-1 enhances metastasis in experimental models (Takaoka et
al, 1997; Yawata et al, 1998) and Shindoh et al (2000) demon-
strated that BAG-1 was expressed in 89% of primary tumours
with nodal metastasis compared to 38% of tumours without.
BAG-1 expression levels were determined by densitometry and
although this alleviates the subjectivity of scoring BAG-1 labelling
intensity to some extent it does not give information on whether
the immunoreactivity is nuclear or cytoplasmic. We examined
BAG-1 expression by immunohistochemistry in paired samples of
primary tumour and matched lymph node metastasis and demon-
strated statistically signiﬁcant increased cytoplasmic expression in 8
of the 13 metastatic tumours relative to the corresponding primary
Table 1 A summary of major studies of BAG-1 expression in breast cancer
Tang et al, 1999 Turner et al, 2001 Sjostrom et al, 2002 Townsend et al, 2002
Number of patients 140 122 126 159
Median age (years) 63 54 (Mean) Not stated 47
Median follow up (years) 8 12.1 Time to progression 4.2 months
Overall survival 9.6 months
12.8
Cohort characteristics Mixed Early stage (I/II) - All wide
excision and radiotherapy
Patients with advanced cancer
entered into chemotherapy trial
Mixed (Pre- and post-
menopausal subgroups)
Antibody used C16 (Santa Cruz Inc.) KS-6C8 Clone not stated C16 (Santa Cruz Inc) (Also TB2)
c
Type Afﬁnity puriﬁed rabbit
Polyclonal
Mouse monoclonal Mouse monoclonal Afﬁnity puriﬁed Rabbit Polyclonal
C-terminal peptide of mouse
Immunogen C-terminal peptide of mouse
BAG-1S
a
GST fusion protein containing
C-terminal 170 amino-acids of
human BAG-1S
GST fusion protein containing
C-terminal 170 amino-acids of
human BAG-1S
BAG-1S
a
Antigen retrieval method Not stated Not stated Boiling in citrate buffer Pressure cooker (citrate buffer)
Scoring system used Intensity H score Percentage of positive cells Intensity
BAG-1 positivity (%)
Nuclear only 18.2 23
b 5
Cytoplasmic only 57.1 65
b 25
Nuclear & cytoplasmic 1.4 62
Total (Nuclear or cytoplasmic) 77.1 Median 60% positive cells 92
Correlations between BAG-1
expression and clinico-
pathological parameters
d
Tumour differentiation
(Nuclear and overall BAG-1)
BCL-2 (cytoplasmic BAG-1) BCL-2, BAX, FasL Grade (Nuclear BAG-1)
ERa status in pre-menopausal
(Cytoplasmic BAG-1)
Correlations between BAG-1
expression and clinical outcome
d
Univariate analysis None DFS,OS (cytoplasmic BAG-1) None None (Trend for improved
survival with nuclear BAG-1)
Multivariate analysis DFS, OS (BAG-1 expression
correlated with poor outcome)
DFS, OS (cytoplasmic BAG-1) None None
aDiffers from human BAG-1S sequence by a single amino acid.
bNuclear+cytoplasmic/cytoplasmic+Nuclear.
cRabbit polyclonal produced using a human BAG-1S-GST fusion
protein as the immunogen; similar staining results were obtained as with C16.
dCorrelations included are those with P values 50.05.
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et al (2000), no signiﬁcant difference in BAG-1 expression was
detected in the primary tumours between patients with and with-
out associated lymph node metastases. We determined the
predominant BAG-1 immunostaining intensity and it is possible
that the maximal intensity may provide improved prognostic value
for metastatic potential. Alternatively, the environment at the site
of the metastasis may induce BAG-1 expression. The presence or
absence of lymph node metastases are of strong prognostic signiﬁ-
cance and evaluation of these events in relation to prognosis in
larger cohorts is warranted.
CONCLUSIONS
Consistent with its effects on a diverse range of important cell
growth control pathways, there is increasing evidence that BAG-1
expression is frequently altered in human cancer. Studies have
focused on breast cancer, non-small cell lung cancer and squamous
cell carcinoma of the head and neck, and there are indications that
BAG-1 expression may also be altered in glioblastoma, cervical
cancer and haemopoietic malignancies (Table 2). Although some
inconsistencies have been reported, there appears to be broad agree-
ment that BAG-1 is overexpressed in breast and non-small cell lung
cancer and that this can correlate with clinical parameters and
improved patient outcome. Further work, including prospective
trials, are required to conﬁrm the exciting possibility that BAG-1
expression might be used as a prognostic marker in early breast
cancer (Turner et al, 2001). Larger prospective studies should be
more representative of the spectrum of breast cancer as a whole
and have increased power to detect independent prognostic predic-
tors in multivariate analysis, in particular in the presence of possible
confounding associations such as tumour grade and ERa status.
As discussed by Turner et al (2001) it is not immediately appar-
ent why an anti-apoptotic protein is associated with good
prognosis. This kind of observation is not unique, however, since
expression of Bcl-2 is also associated with good prognosis in breast
cancer, for example. Multiple alterations contribute to carcinogen-
esis, and tumours that counter apoptosis by overexpressing Bcl-2
and/or BAG-1 might represent one class of tumours. Other
tumours may have disabled apoptotic responses through accumu-
lation of distinct changes (e.g., p53 mutation, ErbB2
overexpression) which might have more profound effects on cell
death sensitivity or additionally affect proliferative pathways result-
ing in more aggressive tumour growth. Effects of BAG-1 on NHR
function in hormone sensitive tumours may also play a role.
Some of the inconsistencies reported will undoubtedly stem
from experimental differences and the subjective nature of immu-
nohistochemical analyses. The signal detected in an
immunohistological assay is not linear with the antibody concen-
tration, nor with many other of the technical parameters
(Wynford-Thomas, 1992). For example in the four breast cancer
studies discussed here, various antibodies, antigen retrieval meth-
ods and scoring systems (intensity vs ‘H-score’) were used, all of
which might have signiﬁcantly inﬂuenced the results (Table 1). A
change in antigen retrieval technique or scoring threshold might
alter the proportion of tumours that are considered to be positive
for expression and might contribute to the variation in detection of
nuclear BAG-1 expression in breast cancer. Such difﬁculties,
amongst others, have been encountered with the immunohisto-
chemical analysis of p53 (Wynford-Thomas, 1992).
Although BAG-1 is part of a family of related proteins, we have
seen no evidence of cross reaction of these antibodies with other
BAG family members, but this remains a theoretical possibility,
especially in antibodies raised against antigens that contain the
conserved BAG domain.
Another important difference between studies is the composi-
tion of the patient cohorts, which are likely to differ in many
ways e.g., menopausal status and stage and treatment. Since all
studies to date are retrospective, the patient selection and exclusion
criteria, treatment protocols and outcome measures are both differ-
ent between studies and not necessarily available in their entirety.
Since BAG-1 can impact on multiple cell control pathways, the
impact of speciﬁc patterns of BAG-1 expression on survival may
depend greatly on the treatment applied in different cohorts. For
example, only BAG-1L regulates ERa function (R Cutress, PA
Townsend and G Packham, unpublished data) and the expression
of nuclear BAG-1L might be particularly important in determining
response to hormonal therapy in breast cancer. By contrast, all
BAG-1 isoforms appear to possess anti-apoptotic activity and
therefore cytoplasmic BAG-1S might be particularly important in
determining responses to chemotherapy. Therefore, the signiﬁcance
of nuclear or cytoplasmic staining might differ depending on the
treatment modality. Unfortunately, there is great heterogeneity
between previous studies as to treatment, and the differences
between these studies must be interpreted in the light of this.
It is also likely that the key targets of BAG-1 will differ between
cell types. For example, ERa is a key regulator of breast epithelial
cells and BAG-1L may therefore be a key determinant of survival in
breast cancer. By contrast, in oral cancer, suppression of retinoid-
induced differentiation may be crucial. Since the BAG-1S isoform
suppresses RAR function, overexpression of BAG-1S might also
be of importance. Thus, we should not expect a simple pattern
of changes in BAG-1 expression in all cancer types due to differ-
ences in ‘key’ BAG-1 targets in different cell types.
A major factor that complicates the interpretation of immunohis-
tochemical analyses stems from the fact that there are multiple BAG-
1 isoforms that can be functionally distinct. The consequences of
high level BAG-1L expression might be very different from those of
relocalisation of cytoplasmic isoforms to the nucleus. Unfortunately,
these proteins are not discriminated by the antibodies currently used
in immunohistochemical analyses of cancer samples. Since the same
mRNA encodes all BAG-1 isoforms it is also not possible to use RNA-
based approaches to measure their relative levels of expression. BAG-
1L-speciﬁc antibodies will be useful in analysing the expression of
speciﬁc BAG-1 isoforms in tumour samples.
Further complexity is added by consideration of issues of func-
tion. It is not known for example if mutations occur within BAG-
1, and if so if these might affect expression levels and what the
functional consequences might be. BAG-1 may be phosphorylated
Table 2 Studies of BAG-1 expression in glioblastoma, cervical carcinoma
leukaemia and lymphoma
Tumour Reference Notes
Glioblastoma Roth et al, 2000 BAG-1 expression was detected in 11/12
human glioma cell lines. Fifteen out of 19
glioblastomas were positive for BAG-1
by immunohistochemistry. In contrast only
single neurones and astrocytes were
positive in normal brain parenchyma.
Cervical carcinoma Yang et al, 1999 BAG-1 overexpression in human cervical
carcinoma biopsies compared to normal
tissue or normal cell lines.
Leukaemia Kitada et al, 1998 Higher levels of BAG-1 in chronic
lymphocytic leukaemia (CLL) were
associated with failure to achieve
complete remission (P=0.04).
Lymphoma Xerri et al, 1999 BAG-1 was detected by immunoblotting
in 33/33 biopsy samples from B cell
non-Hodgkin’s lymphoma. Differences in
expression levels were found between
lymphoma subtypes.
Studies included in the table are those involving primary material.
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signiﬁcance of this and other potential post-translational modiﬁca-
tions (such as BAG-1 ubiquitylation (Sourisseau et al, 2001)) are
poorly understood and presumably not discriminated by immuno-
histochemistry with current antibodies.
It is becoming increasingly clear that expression of BAG-1 is
frequently altered in human cancer and it is possible that expres-
sion analysis might be of clinical utility. Further studies,
including prospective trials, are required and, given the ability of
BAG-1 to target multiple biological pathways, these should be
sufﬁciently large to allow pre-deﬁned subgroup analysis to deter-
mine the effect of BAG-1 on survival in patients treated with
speciﬁc therapeutic regimens (e.g., hormonal therapy vs
chemotherapy). Despite the interesting and encouraging results
obtained from studies of BAG-1 in breast cancer, the ability of
BAG-1 overexpression to promote tumour formation in transgenic
animals is yet to be tested. Such studies may produce compelling
evidence that BAG-1 plays a causal role in cancer development.
The development and application of isoform speciﬁc antibodies
will also be key to characterise the signiﬁcance of speciﬁc BAG-1
isoforms. This should enable dissection of the exact relationship
between differing BAG-1 isoforms and clinical outcome, and to
further clarify the possible role of BAG-1 as a novel prognostic
marker and therapeutic target in a wide range of malignancies.
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